Medical Company Secures Ethics Committee Approval For Major Cancer Trial

Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering medical therapeutic company dedicated to developing advanced treatments for cancer and life-threatening infectious diseases, has reached a milestone in its quest to improve cancer therapy outcomes. On June 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility, and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors. These patients have shown stable or progressive disease during anti-PD-1 monotherapy treatment, including therapies such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab). The approval is valid for a period of three years, until June 13, 2027. This pivotal trial will be conducted by Professor Michael Brown and his experienced team at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia. $Aethlon Medical (AEMD.US)$